Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-11
2006-07-11
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S210030, C546S242000
Reexamination Certificate
active
07074803
ABSTRACT:
The present invention provides high-concentration formulations of opioids such as fentanyl or fentanyl congeners. The formulation of the invention comprises fentanyl or a fentanyl congener in concentrations significantly in excess of conventional formulations, e.g., on the order about 2-fold to about 10,000-fold greater than conventional formulations, e.g., currently commercially available formulations. These formulations are particularly useful for long-term delivery to a subject suffering from pain. The invention further provides drug delivery devices comprising the high-concentration opioid formulations, and further provides methods of alleviating pain in a subject, comprising administering the high-concentration formulations to a subject in need thereof.
REFERENCES:
patent: 3998834 (1976-12-01), Janssen et al.
patent: 4588580 (1986-05-01), Gale et al.
patent: 4769372 (1988-09-01), Kreek
patent: 5202128 (1993-04-01), Morella et al.
patent: 5378474 (1995-01-01), Morella et al.
patent: 5910301 (1999-06-01), Farr et al.
patent: 6113937 (2000-09-01), Vlaminck et al.
patent: 6703483 (2004-03-01), Schiller
patent: 0 267 617 (1988-05-01), None
patent: WO 90/07333 (1990-07-01), None
patent: WO 92/02256 (1992-02-01), None
patent: WO 95/31182 (1995-11-01), None
patent: WO 97/49402 (1997-12-01), None
patent: WO 00/54745 (2000-09-01), None
patent: WO 2004/047839 (2004-06-01), None
Ramsay et al., (1995), “Immobilization of black bears (Ursus americanus) with orally administered carfentanil citrate”,Database Biosis Online!, Biosciences Information Service, Philadelphia, PA US, database accession No. PREV 100598404995, abstract.
Ramsay et al.,“Immobilization of black bears(Ursus americanus)with orally administered carfentanil citrate”, Journal of Wildlife Diseases, (1995), 31(3): 391-393.
Anderson et al. (1998) “Alternate Routes of Opioid Administration in Palliative Care: Phamacologic and Clinical Concerns”J. Pharm. Care Pain Symptom Control6:5-21.
Bruera et al. “Use of the Subcutaneous Route for the Administration of Narcotics in Patients with Cancer Pain”Cancer62:407-11 (1988).
Clotz et al. “Clinical Uses of Fentanyl, Sufentanil, and Alfentanil”Clin. Pharm.10:581-93 (1991).
Fudin et al. “Use of Continuous Ambulatory Infusions of Concentrated Subcutaneous (SQ) hydromorphone versus intravenous (IV) Morphine: Cost Implications for Palliative Care” Am J Hospice Pallitave Care 17:347-353 (2000).
Moulin et al. “Subcutaneous Narcotic Infusions for Cancer Pain: Treatment Outcome and Guidelines For Use”Can. Med. Assoc. J.146:891-7(1992).
Paix et al. “Subcutaneous Fentanyl and Sufentanil Infusion Substitution For Morphine Intolerance In Cancer pain Management”Pain63:263-9 (1995).
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Ativan (2001) pp. 821. , 826, 828, 830, 831, 1193 and 1619.
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Fentanyl (2001) pp. 826.
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Meperidine (2001) pp. 828.
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Morphine (2001) pp. 830.
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Sulfentanil Citrate (2001) pp. 831.
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Hydroxyzine Hydrochlroide (2001) pp. 1193.
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Duramorph (2001) pp. 1195-1197.
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Duragesic (2001) pp. 1573-1577.
Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Dilaudid (2001) pp. 1619-1623.
Scholz et al. (“Clinical Pharmacokinetics of Alfentanil, Fentanyl and Sufentanil”Clin. Pharmacokinet.31:275-92 (1996).
Stephens “Intrathecal Narcotics for Labor Analgesia”Am. Fam. Physician56:463-70 (1997).
Vercauteren et al. “Postoperative Intrathecal Patient-Controlled Analgesia With Bupivacaine, Sufentanil or a mixture of Both”Anaesthesia53:1022-7 (1998).
Wagner et al. “Pharmacokinetics and Pharmacodynamics of Sedatives and Analgesics in the Treatment of Agitated Critically III Patients” Can Pharmakinet 33:426-53 (1997).
White “Clinical Uses of Intravenous Anesthetic and Analgesic Infusions”Anesth. Analg.68:161-171 (1989).
Willens et al. Phamracodynamics, Pharmacokinetics, and Clinical Uses of Fentanyl, Sufentanil, and Alfentanil Heart Lung 22:239-52 (1993).
Laidlaw Barbara J. F.
Litmanovitz Dana
Durect Corporation
Durect Corporation
Hartley Michael G.
McCracken Thomas P.
LandOfFree
Opioid formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opioid formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opioid formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3563258